Neurocrine Biosciences, Inc. $NBIX Position Trimmed by Persistent Asset Partners Ltd
Persistent Asset Partners Ltd significantly reduced its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 59.8% in Q3, selling 12,931 shares. Despite this trim, other major institutional investors like JPMorgan Chase & Co., Norges Bank, and Los Angeles Capital Management LLC increased their holdings. Analyst ratings for NBIX are predominantly "Buy" or "Moderate Buy," with an average price target of $175.84, even as the company recently missed EPS estimates and saw insider selling.
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Fiera Capital Corp
Fiera Capital Corp reduced its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 2.2% in the third quarter, selling 10,918 shares. Despite this, institutional ownership remains high at 92.59%, and analysts generally maintain a "Moderate Buy" rating with an average price target of $175.84, even though the company recently missed EPS estimates but saw significant revenue growth. Several other large institutional investors, including JPMorgan Chase & Co. and AQR Capital Management LLC, increased their holdings in Neurocrine Biosciences during the second quarter.
Aberdeen Group plc Reduces Stock Holdings in Neurocrine Biosciences, Inc. $NBIX
Aberdeen Group plc significantly reduced its stake in Neurocrine Biosciences (NBIX) by 23.9% in Q3, selling 28,241 shares and ending the quarter with 90,045 shares valued at approximately $12.64 million. This move comes as insiders have also been net sellers, with CEO Kyle Gano reducing his ownership by over 20%. Despite missing Q3 EPS estimates, Neurocrine Biosciences saw a 28.3% year-over-year revenue increase, and analysts collectively rate the stock as a "Moderate Buy" with an average price target of $175.84.
Skandinaviska Enskilda Banken AB publ Reduces Holdings in Neurocrine Biosciences, Inc. $NBIX
Skandinaviska Enskilda Banken AB publ has reduced its stake in Neurocrine Biosciences, Inc. by 15.6% in the third quarter, now holding 61,118 shares worth approximately $8.58 million. This comes as insider selling by CEO Kyle Gano and Director Leslie V. Norwalk has also accelerated, with Gano selling 20.6% of his holding and insiders collectively selling 61,966 shares recently. Despite institutional investors owning 92.59% of the stock, Neurocrine Biosciences reported Q3 EPS of $1.88, missing estimates, while revenue increased by 28.3% year-over-year.
Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza
Needham maintains a "Buy" rating on Neurocrine Biosciences (NBIX) despite a slight price target reduction, citing strong growth expectations for Crenessity and Ingrezza in 2026. The firm is optimistic about Neurocrine's pipeline, which includes two active Phase 3 programs that could introduce a new medication every two years. Neurocrine Biosciences, despite not being a traditional psychedelic company, is engaged in developing next-generation neuropsychiatric drugs for conditions like major depressive disorder and schizophrenia.
JPMorgan Chase & Co. Has $664.02 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX
JPMorgan Chase & Co. significantly increased its stake in Neurocrine Biosciences, Inc. by 11.0% in the third quarter, now holding 4,730,152 shares valued at approximately $664.02 million. This increase makes JPMorgan Chase & Co. one of the largest institutional holders of Neurocrine Biosciences stock. Despite the company missing EPS estimates in its most recent quarter, analysts maintain a "Moderate Buy" rating with a consensus target price of $175.84, reflecting overall positive sentiment on future prospects.
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $140.00 by Analysts at Truist Financial
Truist Financial has lowered its price target for Neurocrine Biosciences (NASDAQ:NBIX) to $140.00 from $169.00 but maintained a "buy" rating. This new target represents an 8.10% potential upside from the current stock price, contrasting with the Street's consensus of a "Moderate Buy" and a $175.89 target. The adjustment follows mixed latest-quarter results where EPS missed estimates, but revenue slightly exceeded expectations and saw a significant year-over-year increase.
Truist cuts Neurocrine Bio stock price target on higher spending
Truist Securities lowered its price target for Neurocrine Biosciences (NASDAQ:NBIX) shares to $140 from $169, while maintaining a Buy rating. This adjustment reflects higher anticipated operating expenses, particularly in research and development, despite the company's strong fourth-quarter 2025 earnings and revenues. Other analysts like Canaccord Genuity and H.C. Wainwright also reiterated Buy ratings, with slight price target adjustments, acknowledging the company's progress and market performance.
Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the GARP Strategy with Strong Growth and Reasonable Valuation
Neurocrine Biosciences Inc (NASDAQ:NBIX) has been identified as a strong candidate for the "Growth at a Reasonable Price" (GARP) investment strategy. The company demonstrates robust growth, with significant increases in revenue and EPS, and analysts project this growth to continue. Despite its growth, NBIX appears reasonably valued compared to its biotech industry peers, supported by a debt-free balance sheet and strong profitability.
Wall Street Zen Downgrades Neurocrine Biosciences (NASDAQ:NBIX) to Buy
Wall Street Zen downgraded Neurocrine Biosciences (NASDAQ:NBIX) from "strong-buy" to "buy" due to an EPS miss in Q4 ($1.88 vs. $2.36) despite revenue being up ~28% ($805.5M). This, combined with cautious 2026 guidance, has created near-term uncertainty, though the consensus remains a Moderate Buy with a $177.42 average price target. Insider sales of approximately 61,966 shares ($8.6M) in the last three months also contributed to the cautious outlook.
Neurocrine Biosciences (NBIX) Valuation Check After Strong 2025 Results And Late Stage Pipeline Progress
Neurocrine Biosciences (NBIX) reported strong Q4 and full-year 2025 results with increased revenue and net income, yet its share price has declined recently. Despite this, a common valuation narrative suggests NBIX is 30.9% undervalued, with a fair value of $179.59, supported by its diversified late-stage CNS pipeline. However, its current P/E ratio of 25.9x is above the sector average, indicating a more cautious valuation perspective.
Neurocrine Biosciences (NBIX) Valuation Check After Strong 2025 Results And Late Stage Pipeline Progress
Neurocrine Biosciences (NBIX) reported strong Q4 and full-year 2025 results with increased revenue and net income. Despite this, the stock has recently seen a decline, prompting questions about its current valuation. A key narrative suggests the stock is 30.9% undervalued with a fair value of $179.59, supported by its late-stage CNS pipeline, though risks like pricing pressure on INGREZZA or slower CRENESSITY uptake could impact this outlook.
Neurocrine Biosciences (NBIX) Is Down 12.1% After Issuing 2026 INGREZZA Sales Guidance - What's Changed
Neurocrine Biosciences (NBIX) saw its stock drop 12.1% after releasing its 2025 financial results and 2026 sales guidance for its key drug, INGREZZA. The company reported strong Q4 and full-year 2025 revenues and earnings, with INGREZZA sales guidance set at US$2.70 billion to US$2.80 billion for 2026. This guidance, while supporting the company's strategy of funding a broad CNS pipeline, introduces near-term risks related to pricing pressure and increasing R&D costs.
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment
Neurocrine Biosciences Inc (NBIX) has been identified through a value investing screen as a potentially compelling investment due to its low valuation relative to its industry peers and strong financial health. The company exhibits a debt-free operation, high profitability margins, and robust historical and projected growth in EPS and revenue. Despite its presence in the naturally risky biotechnology sector, its fundamental profile suggests it may be trading below its intrinsic value.
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor
This article summarizes the quarterly earnings reports of Neurocrine Biosciences, Alnylam Pharmaceuticals, and Ascendis Pharma. Neurocrine faced investor concerns about growth potential and margins despite increased sales, while Alnylam's success with Amvuttra led to high expectations, which it still appears poised to meet. Ascendis saw its positive earnings overshadowed by promising Phase 3 data from a rival drug for achondroplasia.
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 9.3% Following Analyst Downgrade
Neurocrine Biosciences (NASDAQ:NBIX) saw its stock price drop by 9.3% after Needham & Company LLC slightly reduced its price target, amidst a Q4 earnings miss and cautious near-term guidance. Despite widespread bullish analyst ratings and an average target price well above the current trading price, insider selling and noted cost pressures contributed to the negative sentiment. Institutional ownership remains high at about 92.6%.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript
Neurocrine Biosciences reported its Q4 and fiscal year 2025 earnings, highlighting total product sales exceeding $2.8 billion, a 22% year-over-year increase, driven by strong INGREZZA performance and the successful launch of CRENESSITY. The company anticipates continued double-digit volume growth for INGREZZA in 2026 and is confident in CRENESSITY becoming its second blockbuster product, despite not providing specific sales guidance for 2026. Neurocrine also detailed advancements in its pipeline, including late-stage neuropsychiatry programs and next-generation VMAT2 inhibitors, emphasizing its strengthened foundation and strategic diversification.
Is Neurocrine Biosciences (NBIX) Pricing Reflecting Its Strong 1 Year Share Performance?
Neurocrine Biosciences (NBIX) has shown a 17.3% return over the past year, but its valuation is mixed based on different models. A Discounted Cash Flow analysis suggests NBIX is undervalued by 56.3% with an estimated intrinsic value of US$314.16 per share, while its current P/E ratio of 32.02x indicates it is overvalued compared to the industry average and Simply Wall St's "Fair Ratio" of 23.83x. The article further explores "Narratives" for NBIX, presenting both bull and bear cases with varying fair value estimates, highlighting the complexities of valuation in the biotech sector.
Neurocrine: Fourth Quarter Earnings Overview
Neurocrine Biosciences reported a net profit of $153.7 million, or $1.48 per share, for the fourth quarter. While their adjusted earnings of $1.88 per share fell short of analyst expectations, the company's revenue of $805.5 million surpassed forecasts. For the full year, Neurocrine achieved a profit of $478.6 million and total annual revenue of $2.86 billion.
Neurocrine Biosciences (NASDAQ: NBIX) posts 2025 INGREZZA surge and details DOJ probe
Neurocrine Biosciences reported strong 2025 financial results, with INGREZZA net product sales reaching $2.51 billion and CRENESSITY generating $301.2 million in its first full launch year. The company is expanding its sales force and advancing a robust pipeline with late-stage programs for osavampator in MDD and direclidine in schizophrenia, both with initial topline data expected in 2027. Neurocrine also disclosed a civil investigative demand from the U.S. Department of Justice regarding INGREZZA sales and marketing practices, to which it is cooperating.
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M
Neurocrine Biosciences, Inc. (NBIX) reported Q4 revenue of $805.5 million, surpassing the FactSet estimate of $790.5 million. The company also announced its fiscal Q4 adjusted earnings and revenue rose, and has set its INGREZZA full-year guidance. This financial update highlights a strong performance exceeding analyst expectations.
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
Neurocrine Biosciences reported strong financial results for the fourth quarter and full-year 2025, with net product sales reaching $798.3 million and $2.83 billion, respectively. The company also provided an optimistic outlook for 2026, forecasting INGREZZA net product sales of $2.7 - $2.8 billion and highlighting significant progress in its clinical pipeline, including Phase 3 programs for osavampator and direclidine. These efforts underscore Neurocrine's commitment to diversifying its biopharmaceutical portfolio and delivering sustained growth.
Neurocrine: Q4 Earnings Snapshot
Neurocrine Biosciences Inc. (NBIX) reported fourth-quarter earnings of $153.7 million, or $1.88 per share adjusted for one-time items, missing analyst estimates of $2.25 per share. The company's revenue of $805.5 million, however, exceeded Street forecasts of $782.9 million. For the full year, Neurocrine posted a profit of $478.6 million on $2.86 billion in revenue.
Neurocrine Biosciences Q4 25 Earnings Conference Call At 4:30 PM ET
Neurocrine Biosciences Inc. (NBIX) will host a conference call on February 11, 2026, at 4:30 PM ET to discuss its Q4 2025 earnings results. Interested parties can access a live webcast via the company's website or listen to the call by dialing the provided conference numbers.
Preview: Neurocrine Biosciences's Earnings
Neurocrine Biosciences (NASDAQ: NBIX) is set to announce its quarterly earnings on February 11, 2026, with analysts estimating an EPS of $2.09. The company has a history of beating EPS estimates but saw a price drop afterward in the last quarter. Analysts currently rate Neurocrine Biosciences as a "Buy" with an average one-year price target of $182.22, indicating a potential 30.57% upside, and the company shows strong revenue growth and net margin compared to peers.
Neurocrine Biosciences (NASDAQ:NBIX) Shareholders Have Earned a 11% CAGR Over the Last Three Years
Neurocrine Biosciences (NASDAQ:NBIX) shareholders have seen an 11% compound annual growth rate (CAGR) over the past three years, with a 19% gain in the last year alone. While the stock's 36% return over three years has lagged the overall market, the company's earnings per share grew by an impressive 92% annually during the same period. This suggests that the market's perception of the stock may have cooled despite strong underlying business performance.
Azzad Asset Management Inc. ADV Acquires New Holdings in Neurocrine Biosciences, Inc. $NBIX
Azzad Asset Management Inc. ADV has acquired new holdings in Neurocrine Biosciences (NASDAQ: NBIX), purchasing 8,946 shares valued at approximately $1.256 million in Q3, bringing institutional ownership to about 92.59%. Despite recent insider selling totaling $8.63 million, analysts maintain a "Moderate Buy" rating with an average target price of $174. The company, which specializes in treatments for neurological, endocrine, and neuropsychiatric disorders, has seen its stock trading up by 2.4% with a market capitalization of $14.08 billion.
Neurocrine’s New Tardive Dyskinesia Trial And What It Means For Valuation
Neurocrine Biosciences has initiated a Phase 2 clinical trial for NBI-1065890, a new investigational compound for tardive dyskinesia, aiming to develop a differentiated, longer-acting treatment. This trial leverages the company's established expertise in movement disorders and its existing VMAT2 inhibitor franchise. While still in early stages, the outcome could significantly influence Neurocrine’s pipeline strategy and its valuation within the neurological and psychiatric conditions sector.
The Bull Case For Neurocrine Biosciences (NBIX) Could Change Following Its Next-Gen VMAT2 Phase 2 Trial
Neurocrine Biosciences has launched a Phase 2 trial for NBI-1065890, a next-generation VMAT2 inhibitor for tardive dyskinesia, aiming for longer-acting treatment options. While this trial is not an immediate catalyst, it supports the company's long-term strategy of pipeline expansion beyond its current core product, INGREZZA. Despite the company's profitability and stock buybacks, investors should consider the concentration risk with INGREZZA and potential valuation disparities.
Neurocrine’s New Tardive Dyskinesia Trial And What It Means For Valuation
Neurocrine Biosciences has initiated a Phase 2 clinical trial for NBI-1065890, an investigational compound for tardive dyskinesia, building on its existing expertise in movement disorders. This trial aims to explore a potentially longer-acting treatment option, which could influence the company's future tardive dyskinesia portfolio. While early stage, the study may impact Neurocrine's valuation and strategic positioning within neurological and psychiatric conditions.
Neurocrine Biosciences, Inc. $NBIX Shares Sold by C WorldWide Group Holding A S
C WorldWide Group Holding A S recently trimmed its stake in Neurocrine Biosciences (NBIX) by 7.4% in the third quarter, reducing its holding to 125,000 shares valued at approximately $17.55 million. Despite this, other institutional investors have increased their positions. Analysts maintain a "Moderate Buy" rating with a consensus price target of $174.25, while insider selling has also been noted, with 61,966 shares sold over the past 90 days.
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Savant Capital LLC
Savant Capital LLC significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 57.7% in Q3, now holding 36,659 shares valued at $5.15 million. Other institutional investors like Allspring Global Investments and Arrowstreet Capital also boosted their positions, leading to hedge funds and institutional investors owning about 92.59% of NBIX. Despite analyst consensus being a "Moderate Buy" with a $174.25 target, company insiders, including CEO Kyle Gano, have been net sellers in the last 90 days, offloading over 61,000 shares worth approximately $8.63 million.
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards?
Neurocrine Biosciences is set to report its fourth-quarter 2025 results on February 11, with analysts expecting revenues of $784.42 million and EPS of $2.27. The company's growth is primarily driven by strong sales of its marketed drugs, Ingrezza and Crenessity, and royalty income, all of which are expected to contribute to a year-over-year revenue jump. Investors will also be keen on updates regarding its late-stage pipeline, including direclidine for schizophrenia and osavampator for major depressive disorder.
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards?
Neurocrine Biosciences (NBIX) is set to report its fourth-quarter 2025 results on Feb. 11, with investors focusing on the sales performance of Ingrezza and Crenessity, as well as pipeline updates. The company expects revenue growth driven by increased sales of marketed drugs and higher collaboration revenues. Despite a mixed earnings surprise history, NBIX has an Earnings ESP of +1.90%, though it currently holds a Zacks Rank #4 (Sell).
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Wall Street anticipates Neurocrine Biosciences (NBIX) will report significant year-over-year earnings and revenue growth for the quarter ended December 2025. While a strong consensus outlook is positive, the actual results compared to these estimates will be crucial for the stock's immediate price action. The company's Earnings ESP suggests a potential for an earnings beat, though its Zacks Rank of #4 makes a conclusive prediction difficult.
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Neurocrine Biosciences (NBIX) is projected to report a significant year-over-year increase in earnings and revenues for the quarter ended December 2025, with EPS expected to grow by 127% and revenues by 25%. Despite a positive Earnings ESP, the stock currently holds a Zacks Rank #4 (Sell), making a conclusive prediction about an earnings beat difficult. Investors are advised to consider other factors in addition to the earnings forecast.
Neurocrine Biosciences (NBIX) Projected to Post Earnings on Wednesday
Neurocrine Biosciences (NBIX) is projected to report its Q4 2025 earnings after market close on Wednesday, February 11th, with analysts expecting $2.36 EPS and $804.21 million in revenue. Recent insider selling includes CEO Kyle Gano's sale of 36,400 shares, and institutional investors have adjusted their positions. The company holds a "Moderate Buy" consensus rating with an average price target of $174.25.
Trading the Move, Not the Narrative: (NBIX) Edition
This article analyzes Neurocrine Biosciences Inc. (NASDAQ: NBIX), highlighting strong near-term sentiment and a long-term positive bias. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also details a multi-timeframe signal breakdown for NBIX.
Short Interest in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Declines By 13.9%
Neurocrine Biosciences (NASDAQ:NBIX) saw a 13.9% decrease in short interest in January, totaling 3,501,097 shares. Analysts maintain a "Moderate Buy" consensus with an average target price of $174.25, despite recent insider selling. The company, which focuses on treatments for neurological, endocrine, and neuropsychiatric disorders, has 3.7% of its shares short sold.
How Investors Are Reacting To Neurocrine Biosciences (NBIX) Launching Phase 2 Trial For Longer-Acting TD Drug
Neurocrine Biosciences (NBIX) has initiated a Phase 2 trial for NBI-1065890, a longer-acting VMAT2 inhibitor for tardive dyskinesia, building on its established valbenazine franchise. This move, part of the company's two decades of VMAT2 research, aims to enhance its product pipeline. While analysts' fair value estimates vary widely, the company's strong financials and existing VMAT2 focus are central to its investment narrative, though R&D execution risks remain.
How Investors Are Reacting To Neurocrine Biosciences (NBIX) Launching Phase 2 Trial For Longer-Acting TD Drug
Neurocrine Biosciences (NBIX) has initiated a Phase 2 trial for NBI-1065890, a longer-acting drug for tardive dyskinesia, extending its VMAT2 research. This trial is not expected to significantly alter near-term catalysts but slightly increases R&D risk. Despite strong financials and a solid pipeline, the stock has underperformed the biotech sector, trading at a higher earnings multiple than peers.
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 31.99% Upside Potential for Investors
Neurocrine Biosciences, Inc. (NBIX) presents an exciting investment opportunity in the drug manufacturing sector, with analysts projecting a 31.99% upside potential and an average target price of $179.59. The company exhibits robust financial health with significant revenue growth, an impressive return on equity, and strong free cash flow. Its strategic product pipeline and collaborations further enhance its market position, making it an attractive prospect for growth-oriented investors despite the absence of dividends.
Bank of New York Mellon Corp Has $106.89 Million Position in Neurocrine Biosciences, Inc. $NBIX
Bank of New York Mellon Corp has a significant position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX), holding 761,396 shares valued at approximately $106.89 million, despite trimming its stake by 2.2% in the third quarter. Institutional investors and hedge funds own 92.59% of the company, while insiders have been net sellers, divesting over $11 million in shares recently. Analysts largely maintain a positive outlook, with a consensus "Moderate Buy" rating and an average price target of $174.25.
Thrivent Financial for Lutherans Sells 215,514 Shares of Neurocrine Biosciences, Inc. $NBIX
Thrivent Financial for Lutherans reduced its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 27.4%, selling 215,514 shares, leaving it with 571,785 shares valued at approximately $80.27 million. This comes amidst significant insider selling, with directors and other insiders disposing of shares worth $11.4 million in the last three months. Despite this, analyst sentiment remains largely positive, with a "Moderate Buy" rating and an average price target of $174.25.
Atle Fund Management AB Has $14.41 Million Position in Neurocrine Biosciences, Inc. $NBIX
Atle Fund Management AB significantly increased its stake in Neurocrine Biosciences (NBIX) by 16.1% in Q3, making it their third-largest holding with a value of approximately $14.41 million. Despite high institutional ownership, insiders, including the CEO, have been net sellers of shares. Analysts maintain a "Moderate Buy" rating for NBIX with a consensus price target of $174.25, suggesting potential upside from its current trading level.
Neurocrine Biosciences (NBIX) Valuation Check After New Mid Stage VMAT2 Inhibitor Trial Update
Neurocrine Biosciences (NBIX) has initiated a Phase 2 trial for NBI-1065890, a new VMAT2 inhibitor for tardive dyskinesia, prompting a re-evaluation of its stock. Despite recent share price declines, the company shows positive longer-term shareholder returns, and its valuation suggests it might be undervalued with a narrative fair value of $179.66 against a current price of $136.06. However, its P/E ratio is higher than industry averages, indicating potential premium pricing that leaves less room for error.
Neurocrine Biosciences (NBIX) Valuation Check After New Mid Stage VMAT2 Inhibitor Trial Update
Neurocrine Biosciences (NBIX) has initiated a Phase 2 trial for NBI-1065890, a new VMAT2 inhibitor for tardive dyskinesia, which could be a significant pipeline development for investors. Despite recent declines in short-term share price performance, longer-term returns are positive, and the stock is considered "24.3% Undervalued" trading at $136.06 against a narrative fair value of $179.66. However, its P/E ratio of 31.7x is higher than the industry average, suggesting less room for error if market expectations shift.
Y Intercept Hong Kong Ltd Makes New Investment in Neurocrine Biosciences, Inc. $NBIX
Y Intercept Hong Kong Ltd has acquired a new stake of 11,183 shares in Neurocrine Biosciences, Inc. (NBIX) during Q3, valued at approximately $1.57 million. This new investment comes as Neurocrine Biosciences reported strong Q3 earnings, beating analyst expectations with $2.17 EPS and $794.9 million in revenue, leading to several analyst price target increases. Despite institutional buying, company insiders, including CEO Kyle Gano, have been net sellers of the stock.
AlphaQuest LLC Boosts Stock Holdings in Neurocrine Biosciences, Inc. $NBIX
AlphaQuest LLC significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) during the third quarter, boosting its holdings by 3,271.5% to 13,149 shares valued at approximately $1.85 million. This comes as other institutional investors have also adjusted their positions in the company, which recently reported strong Q3 earnings exceeding expectations. Neurocrine Biosciences currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $174.25, while institutional investors own about 92.59% of the stock.
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup
Neurocrine Biosciences Inc. (NASDAQ:NBIX) is highlighted as an attractive investment due to its strong fundamentals and bullish technical setup. The company demonstrates impressive revenue growth, high profitability margins, a debt-free balance sheet, and a strong Altman-Z score. Technically, NBIX is in a sideways trading phase, potentially signaling an upcoming upward movement, making it a compelling opportunity for investors seeking growth stocks with solid underlying business strength.
